A Phase 2 interventional study of Ruxolitinib in Hemophagocytic Syndromes, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-02-06.
Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing ruxolitinib in Lymphohistiocytosis, Hemophagocytic — 5 open to participants now, 6 under way, none of them phase 3. ruxolitinib · Lymphohistiocytosis, Hemophagocytic.
Among the 10 studies testing ruxolitinib in Lymphohistiocytosis, Hemophagocytic, this one is the 5th largest by planned enrollment, is one of 3 that started in 2024, is one of 4 in phase 2, and was the 9th registered.
111 studies on the registry are indexed under Lymphohistiocytosis, Hemophagocytic; 41 are open to participants now.
Browse Lymphohistiocytosis, Hemophagocytic studies →5 of the 10 studies testing ruxolitinib in Lymphohistiocytosis, Hemophagocytic are open now, in 3 countries. Recruiting first, the newest first:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18–99
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages up to 22
Jerry Lee, MD, MSc, MPhil · Sites in United States
Ages 18+
The Children's Hospital of Zhejiang University School of Medicine · Sites in China
Ages 1 days–18 yrs
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 26 Lymphohistiocytosis, Hemophagocytic studies recruiting now, 14 (54%) set no upper age limit and 8 (31%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 1 · Phase 4 2
First in 2016; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 42 is above the median of 30 across 75 interventional studies indexed under Lymphohistiocytosis, Hemophagocytic.
Median enrollment 36 across the 10 interventional studies. Of the 1 that completed or were terminated, 1 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 9 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 6 studies filed under Lymphohistiocytosis, Hemophagocytic — fewer than ten, so there is no comparison to draw.
1 of the studies testing ruxolitinib in Lymphohistiocytosis, Hemophagocytic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05762640Assistance Publique - Hôpitaux de ParisRuxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH) | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing ruxolitinib in Lymphohistiocytosis, Hemophagocytic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Hemophagocytic syndrome (HS) is a rare condition that can be responsible for severe organ failure. Therapeutic guidelines are mainly based on observational studies and expert opinions: no therapeutic advance has been developed for years, explaining why mortality in HS remains high (Intensive Care Unit mortality ranging from 40 to 70%). If etoposide remains the gold standard in critically ill HS patients, nearly 20% of patients are refractory to this therapy: treatment escalation is common, most often requiring the administration of intensive treatments generating high toxicity. Ruxolitinib is the first approved JAK inhibitor. It has been associated with improvement of HS manifestations and survival in a pre-clinical murine model. Data in humans are scarce but promising.
The aim is to demonstrate that ruxolitinib, in association with standard of care, may reverse organ failure (as represented by Sequential Organ Failure Assessment (SOFA) score) better than standard of care alone in critically ill patients with acquired HS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
signed:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ruxolitinib
Oral ruxolitinib twice a day (10 mg x 2 during 28 days) in association with standard of care in HS.
Survival with a decrease in SOFA score ≥ 3 points
Sequential Organ Failure Assessment Score varies from 0 to 4 and permit to assess organ failure. A higher score indicates better neurological function.
Time frame: At day 7
Overall survival in HS critically ill patients
Time frame: At 6 months
SOFA score
Sequential Organ Failure Assessment Score varies from 0 to 4 and permit to assess organ failure. A higher score indicates better neurological function.
Time frame: At day 1
SOFA score
Sequential Organ Failure Assessment Score varies from 0 to 4 and permit to assess organ failure. A higher score indicates better neurological function.
Time frame: At day 14
SOFA score
Sequential Organ Failure Assessment Score varies from 0 to 4 and permit to assess organ failure. A higher score indicates better neurological function.
Time frame: At day 28
Length of stay in Intensive Care Unit
number of days in the ICU from inclusion to ICU discharge or death
Time frame: Up to 6 months
Hospital length of stay
number of days in the hospital from inclusion to hospital discharge or death
Time frame: Up to 6 months
Measurement of clinical and biological manifestations
Measurements of temperature, ferritin level, CD25 soluble receptor dosage, fibrinogen level, triglycerides level, haemoglobin level, white blood cells count, platelets count
Time frame: At day 1
Measurement of clinical and biological manifestations
Measurements of temperature, ferritin level, CD25 soluble receptor dosage, fibrinogen level, triglycerides level, haemoglobin level, white blood cells count, platelets count
Time frame: At day 7
Measurement of temperature
Time frame: At day 14
Measurement of temperature
Time frame: At day 28
Measurement of ferritin level
Time frame: At day 14
Measurement of ferritin level
Time frame: At day 28
Measurement of CD25 soluble receptor dosage
Time frame: At day 14
Measurement of CD25 soluble receptor dosage
Time frame: At day 28
Measurement of fibrinogen level
Time frame: At day 14
Measurement of fibrinogen level
Time frame: At day 28
Measurement of triglycerides level
Time frame: At day 14
Measurement of triglycerides level
Time frame: At day 28
Measurement of haemoglobin level
Time frame: At day 14
Measurement of haemoglobin level
Time frame: At day 28
Measurement of white blood cells count
Time frame: At day 14
Measurement of white blood cells count
Time frame: At day 28
Platelets count
Time frame: At day 14
Platelets count
Time frame: At day 28
Dosages of IL2, IL6, IL10, IL12, GM-CSF, IFN gamma, TNF alpha
Time frame: At day 1
Dosages of IL2, IL6, IL10, IL12, GM-CSF, IFN gamma, TNF alpha
Time frame: At day 7
Dosages of IL2, IL6, IL10, IL12, GM-CSF, IFN gamma, TNF alpha
Time frame: At day 14
Dosages of IL2, IL6, IL10, IL12, GM-CSF, IFN gamma, TNF alpha
Time frame: At day 28
Incidence of nosocomial infections (viral and bacterial)
Time frame: Until day 28
Incidence of adverse event, severe adverse event
Intensity and frequency of adverse event and severe adverse event according to the CTCAE Toxicity Grading Scale for Determining The Severity of Adverse Events
Time frame: Until day 28
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Feb 2024; primary completion for Aug 2025, 18 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib
Lymphohistiocytosis, Hemophagocytic →
Assistance Publique - Hôpitaux de Paris →